-
公开(公告)号：WO2018199628A1
公开(公告)日：2018-11-01
申请号：PCT/KR2018/004800
申请日：2018-04-25
Applicant: 성균관대학교산학협력단
Abstract: 본원은 약독화된 폐렴구균 균주를 포함하는 약제학적 조성물, 및 이의 염증성 질환, 호흡기 바이러스 감염, 세균 감염성 질환 또는 알레르기성 질환의 예방 또는 치료를 위한 용도에 관한 것이다.
-
公开(公告)号：WO2018236185A2
公开(公告)日：2018-12-27
申请号：PCT/KR2018/007102
申请日：2018-06-22
Applicant: 성균관대학교산학협력단
Abstract: 본원은 폐렴구균의 VncRS 오페론 억제제 또는 락토페린 활성 억제제를 포함하는 패혈증의 예방 또는 치료용 약제학적 조성물, 및 패혈증의 예방 또는 치료제의 스크리닝 방법에 관한 것이다.
-
公开(公告)号：WO2013039327A2
公开(公告)日：2013-03-21
申请号：PCT/KR2012/007324
申请日：2012-09-12
Applicant: 성균관대학교산학협력단 , 이동권 , 김은혜
CPC classification number: C12Q1/32 , G01N2333/3156 , G01N2500/04
Abstract: 본 발명은 폐렴구균( Streptococcus pneumoniae )의 알코올탈수소효소(alcohol dehydrogenase)를 이용한 치료제, 예방제 및 항생물질 스크리닝 방법에 관한 것으로, 보다 구체적으로는 세포 외부로 분비되며 병원성에 필수적인 기능을 하는 폐렴구균의 알코올탈수소효소를 이용하여 항생물질을 스크리닝하는 방법에 관한 것이다. 본 발명에서 제공하는 폐렴구균의 알코올탈수소효소를 이용한 스크리닝 방법 및 키트는, 실험방법이 간단하며 검출시간이 짧기 때문에 단 시간에 대량의 물질을 스크리닝하는데 이용할 수 있을 것으로 기대된다.
Abstract translation: 本发明涉及一种用于筛选治疗和预防药物的方法，以及使用肺炎链球菌的醇脱氢酶的抗生素，更具体地，涉及使用分泌在细胞外的肺炎链球菌的醇脱氢酶筛选抗生素的方法 并在致病性中发挥重要作用。 由于简单的实验方法和短的检测时间，本发明提供的使用本发明提供的肺炎链球菌的醇脱氢酶的筛选方法及其试剂盒预期用于在短时间内筛选大量的材料。
-
-
5.发明公开ｓｐｒ1709 유전자가 손상된 변이주를 이용한 폐렴구균을 치료하기 위한 약독화 백신 및 이의 진단방법 无效用于使用包含突变的SPR1709基因的突变体治疗肺炎支原体的衰老疫苗及其诊断方法
公开(公告)号：KR1020100034206A
公开(公告)日：2010-04-01
申请号：KR1020080093229
申请日：2008-09-23
Applicant: 성균관대학교산학협력단 , 대한민국(관리부서 질병관리본부장)
CPC classification number: C12Q1/689 , C12Q2561/113 , C12Q2600/112
Abstract: PURPOSE: A vaccine using a mutant of spr1709 gene expressed in human lung cell infection and a method for diagnosing Streptococcus pneumonize mutant are provided to prevent pneumococcal pneumonia and develop a therapeutic agent. CONSTITUTION: A Streptococcus pneumonia mutant has spr1709 gene of which function is damaged. The deleted site of the gene is 1681098th to 1682261th. A primer set for preparing DNA for inducing mutation is denoted by sequence number 2-7. The Streptococcus pneumonia is D39. A vaccine composition for treating Streptococcus pneumonia contains the mutant of Streptococcus pneumonia and pharmaceutically acceptable carrier. The vaccine composition is administered through aerosol, spot delivery system.
Abstract translation: 目的：提供使用人类肺细胞感染中表达的spr1709基因突变体的疫苗和肺炎链球菌突变体的诊断方法，以预防肺炎球菌肺炎并开发治疗剂。 构成：肺炎链球菌突变体具有功能损伤的spr1709基因。 该基因的缺失位点为1681098〜1682261。 用于制备用于诱导突变的DNA的引物组由序列号2-7表示。 肺炎链球菌是D39。 用于治疗肺炎链球菌的疫苗组合物含有肺炎链球菌和药学上可接受的载体的突变体。 疫苗组合物通过气雾剂，斑点递送系统施用。
-
Patent Agency Ranking
公开(公告)号：KR1020080061327A
公开(公告)日：2008-07-02
申请号：KR1020070139111
申请日：2007-12-27
Applicant: 성균관대학교산학협력단
Inventor： 이동권
IPC: A61K31/575 , A61P35/00
CPC classification number: A61K31/575 , A23L29/035 , A23V2200/308
Abstract: A composition comprising soluble UDCA(ursodeoxycholic acid) is provided to improve therapeutic effects on colon cancer by increasing solubility of UDCA and pH stability for maintaining soluble state of UDCA in the stomach and inhibit toxicity, so that the composition is useful for prevention and treatment of colon cancer. A composition for prevention and treatment of colon cancer comprises soluble UDCA which is prepared by dissolving UDCA with maltodextrin or liquid glucose such as light corn syrup in water, and if necessary, pH of soluble UDCA is regulated with acid selected from nitric acid, sulfuric acid, citric acid, phosphoric acid or lactic acid, or base, and pharmaceutically acceptable carriers, diluents or excipients.
Abstract translation: 提供包含可溶性UDCA（熊去氧胆酸）的组合物以通过增加UDCA的溶解度和pH稳定性来改善对结肠癌的治疗效果，以维持UDCA在胃中的可溶性状态并抑制毒性，使得该组合物可用于预防和治疗 结肠癌。 用于预防和治疗结肠癌的组合物包括可溶性UDCA，其通过将UDCA与麦芽糖糊精或液体葡萄糖如轻玉米糖浆溶解在水中而制备，并且如果需要，可溶性UDCA的pH由选自硝酸，硫酸 ，柠檬酸，磷酸或乳酸或碱，以及药学上可接受的载体，稀释剂或赋形剂。
-
公开(公告)号：KR1020130030210A
公开(公告)日：2013-03-26
申请号：KR1020120101048
申请日：2012-09-12
Applicant: 성균관대학교산학협력단
Abstract: PURPOSE: A method for screening a material using alcohol dehydrogenase of Streptococcus pneumoniae is provided to quickly screen a large amount of a material. CONSTITUTION: A method for screening an antibiotic material comprises: a step of treating a test material to Streptococcus pneumoniae and culturing; a step of adding a phosphate buffer containing nicotinamide adenine dinucleotide and alcohol; and a step of measuring the generation quantity of nicotinamide adenine dinucleotide. Alcohol dehydrogenase is used as a marker. The test material is selected from chemicals, microbial culture media, microbial extracts, nucleic acid, antibodies, aptamers, and natural product extracts.
Abstract translation: 目的：提供使用肺炎链球菌醇脱氢酶筛选材料的方法，以快速筛选大量的材料。 构成：筛选抗生素材料的方法包括：将试验材料处理至肺炎链球菌并培养的步骤; 加入含有烟酰胺腺嘌呤二核苷酸和醇的磷酸盐缓冲液的步骤; 以及测定烟酰胺腺嘌呤二核苷酸的产生量的步骤。 酒精脱氢酶用作标记物。 测试材料选自化学品，微生物培养基，微生物提取物，核酸，抗体，适体和天然产物提取物。
-
公开(公告)号：KR1020120010906A
公开(公告)日：2012-02-06
申请号：KR1020100072581
申请日：2010-07-27
Applicant: 성균관대학교산학협력단
Abstract: PURPOSE: An attenuated Streptococcus pneumococcus containing mutant pep27 is provided to ensure excellent vaccine effect and to minimize inconvenience. CONSTITUTION: An attenuated Streptococcus pneumococcus contains mutant pep27 gene. The pep27 gene encodes an amino acid of pep27 peptides of sequence number 1. A method for preparing the attenuated Streptococcus pneumococcus comprises a step of deleting the pep27 gene in chromosome DNA. A vaccine composition for preventing or treating Streptococcus pneumococcus infectious diseases contains the Streptococcus pneumococcus strain. The vaccine composition immunizes by a serotype-independent method.
Abstract translation: 目的：提供减毒的含有链球菌的肺炎链球菌突变型pep27，以确保优异的疫苗效果并减少不便。 构成：减毒型肺炎链球菌含有突变型pep27基因。 pep27基因编码序列号1的pep27肽的氨基酸。制备减毒的肺炎链球菌的方法包括删除染色体DNA中pep27基因的步骤。 用于预防或治疗肺炎链球菌感染性疾病的疫苗组合物含有肺炎链球菌菌株。 疫苗组合物通过不依赖血清型的方法免疫。
-
9.发明公开ｓｐｒ0526, ｓｐｒ0527, 및 ｓｐｒ0528 유전자가 손상된 변이주를 이용한 폐렴구균을 치료하기 위한 약독화 백신 및이의 진단 방법 无效使用含有突变型SPR0526，SPR0527和SPR0528基因的突变体治疗肺炎支原体的灭菌疫苗及其诊断方法
公开(公告)号：KR1020100034201A
公开(公告)日：2010-04-01
申请号：KR1020080093216
申请日：2008-09-23
Applicant: 성균관대학교산학협력단 , 대한민국(관리부서 질병관리본부장)
CPC classification number: C07K14/3156 , A61K39/092 , A61K2039/522 , C12Q1/6876 , C12Q2600/136
Abstract: PURPOSE: A vaccine using damaged mutant of spr0526, spr0527 and spr0528 and a method for diagnosing Streptococcus pneumonia are provided to apply to all Streptococcus pneumonia and initially defense from the Streptococcus pneumonia. CONSTITUTION: A Streptococcus pneumonia mutant has damaged spr0526, spr0527, and spr0528. A deleted site is from 534172 to 535222 of the total Streptococcus pneumonia. A primer set for manufacturing DNA for inducing mutation is denoted by sequence number 2-7. The mutant of Streptococcus pneumonia is introduced. The Streptococcus pneumonia is d39.
Abstract translation: 目的：提供使用spr0526，spr0527和spr0528的损伤突变体的疫苗以及肺炎链球菌诊断方法，适用于所有肺炎链球菌，并初步防治肺炎链球菌。 构成：肺炎链球菌突变体损伤了spr0526，spr0527和spr0528。 删除的位点是总链球菌肺炎的534172至535222。 用于制造用于诱导突变的DNA的引物组由序列号2-7表示。 介绍了肺炎链球菌的突变体。 肺炎链球菌是d39。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.02 seconds)
